Thompson Jaye 4
4 · Greenwich LifeSciences, Inc. · Filed Jun 24, 2022
Insider Transaction Report
Form 4
Thompson Jaye
VP Clinical & Reg Affairs
Transactions
- Award
Stock Options
2022-06-22+149,818→ 149,818 totalExercise: $7.63Exp: 2032-06-22→ Common Stock (149,818 underlying)
Footnotes (1)
- [F1]The options vest over time and pursuant to milestones. 3,121 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.